Table 4.

Evaluation of the admission and end of treatment laboratory parameters in nonsevere and severe groups with COVID-19

	Nonsevere group (n = 85)				Severe group (n = 35)
	Admission	End of treatment	Z	P	Admission	End of treatment	Z	P
Leucocytes	5150 (2230–10 850)	5410 (662–11 770)	−0.082	0.935	5970 (2810–16 520)	6710 (3460–14 340)	−1.245	0.213
Neutrophils	3110 (1110–8120)	2830 (4040–7090)	−2.498	0.013	4270 (1740–13 770)	4390 (3370–13 270)	−0.082	0.935
Lymphocytes	1330 (390–3030)	1770 (390–3800)	−5.258	<0.001	1090 (560–2070)	1080 (240–2690)	−1.786	0.074
Monocytes	380 (40–940)	350 (140–890)	−0.875	0.382	330 (40–1380)	400 (190–770)	−1.753	0.08
Eosinophils	40 (0–290)	80 (0–320)	−4.391	<0.001	30 (0–150)	90 (10–310)	−3.739	<0.001
Basophils	20 (0–170)	20 (0–160)	−1.251	0.211	30 (0–600)	20 (10–70)	−1.003	0.316
RBCs	4.93 (3.98–5.82)	4.72 (3.88–5.89)	−4.307	<0.001	4.81 (3.97–5.79)	4.57 (3.68–5.83)	−3.686	<0.001
Haemoglobin	14.5 (9.6–17.7)	13.8 (9.2–17.9)	−4.617	<0.001	13.8 (11.2–17.4)	12.6 (10.1–15.7)	−4.359	<0.001
Haematocrit	42 (15.2–52.5)	40.5 (29.8–53.5)	−3.874	<0.001	40.2 (33.9–49.7)	37.7 (31.1–96.6)	−2.933	0.003
RDW	13.3 (11.7–27.3)	13.3 (11.9–17.6)	−1.855	0.064	13.5 (12.3–17.1)	13.4 (12.1–17.2)	−1.521	0.128
Platelets	217000 (119000–488000)	231000 (104000–441000)	−2.268	0.023	221000 (131000–506000)	357000 (135000–654000)	−4.66	<0.001
Platecrit	0.18 (0.1–0.37)	0.19 (0.08–0.37)	−2.123	0.034	0.18 (0.1–0.41)	0.28 (0.12–0.57)	−4.588	<0.001
DNI	0.1 (0.1–9.5)	0.1 (0.1–5.5)	−2.769	0.006	0.1 (0.1–4.4)	0.1 (0–6.4)	−0.056	0.955
NLR	2.31 (0.47–9.63)	1.52 (0.57–7.29)	−5.335	<0.001	4.04 (1.51–15.54)	3.72 (0.64–40)	−0.901	0.368
PLR	170 (60–620)	130 (60–420)	−4.237	<0.001	220 (100–490)	300 (300–940)	−3.317	0.001

RDW, red cell distribution width; MPV, mean platelet volume; PDW, platelet distribution width; DNI, delta neutrophil index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; RBCs, red blood cells.

Wilcoxon's signed ranks analysis. Data are median (min-max).